Eton Pharmaceuticals, Inc.
ETON · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 23.3% | 48.9% | -2.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 60% | 66.6% | 67.4% | 88% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3.7% | -0.9% | -30.5% | -4.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -9.8% | -3% | -42.4% | -9% |
| EPS Diluted | -0.15 | -0.037 | -0.36 | -0.078 |
| % Growth | -311% | 89.9% | -363.9% | – |
| Operating Cash Flow | $0 | $0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | -$0 |